Drug Trial Radar · NCT06353347
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
551
Actual
Start
Nov 13, 2023
Primary completion
Dec 12, 2024
Study completion Jul 30, 2025
Sponsor
- Lead sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes inadequately controlled with metformin.
Conditions
- Type 2 Diabetes Mellitus
Interventions
HTD1801Drug
HTD1801 1000 mg administered orally BID as four capsules
PlaceboDrug
Matching placebo administered orally BID as four capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Endpoint: mean change in HbA1cTime frame: 24 Weeks
Locations
64 sites in 1 country. Site status is shown where the registry gives one.
Baogang Hospital of Inner Mongolia
Baotou, China
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Beijing Luhe Hospital Capital Medical University
Beijing, China
Beijing Pinggu Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
The Second Norman Bethune Hospital of Jilin University
Changchun, China
The First People's Hospital of Changde City
Changde, China
Hunan Provincial People's Hospital
Changsha, China
The Third Xiangya Hospital of Central South University
Changsha, China
Chongqing University Three Gorges Hospital
Chongqing, China
The Third People's Hospital of Datong
Datong, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
Handan First Hospital
Handan, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, China
Anhui Provincial Hospital
Hefei, China
The Second Hospital of Anhui Medical University
Hefei, China
Hengshui People's Hospital (Harrison International Peace Hospital)
Hengshui, China
Heze Municipal Hospital
Heze, China
Huai'an First People's Hospital
Huai'an, China
Huangshi Central Hospital
Huangshi, China
Huizhou Municipal Central Hospital
Huizhou, China
Huzhou Central Hospital
Huzhou, China
Jinan Central Hospital
Jinan, China
Jingzhou Central Hospital
Jingzhou, China
Jinzhou Central Hospital
Jinzhou, China
The First People's Hospital of Kashgar
Kashgar, China
Hebei Petro China Center Hospital
Langfang, China
Liaocheng People's Hospital
Liaocheng, China
The First Affiliated Hospital of Henan University of Science and Technology (Jinghua)
Luoyang, China
The First Affiliated Hospital of Henan University of Science and Technology (Kaiyuan)
Luoyang, China
Nanjing Drum Tower Hospital - The Affiliated Hospital of Nanjing University Medical School
Nanjing, China
Nanjing First Hospital
Nanjing, China
Nanjing Jiangning Hospital
Nanjing, China
Sir Run Run Hospital Nanjing Medical University
Nanjing, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
The First People's Hospital of Nanning
Nanning, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, China
Panjin Liaohe Oilfield Gem Flower Hospital
Panjin, China
The First Hospital of Qiqihar
Qiqihar, China
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.